Coronavirus Resources: COVID-19 Information and Our Scientific Efforts

Our scientific efforts played a key role during a massive healthcare collapse. Read about SARS-CoV-2, the coronavirus that causes COVID-19, and Pfizer's work during the pandemic.

What is COVID-19?

Coronaviruses form a large genus of microorganisms that cause human respiratory illness, ranging from the common cold to severe disease. 1 The coronavirus responsible for the pandemic that began in 2019 is called acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2 The disease it causes is called "coronavirus disease 2019" or "COVID-19". 2

Our Commitment to Fighting COVID-19

From the very beginning of the pandemic, we recognized that fighting COVID-19 would require the power of science and unprecedented collaboration among scientists, companies, governments, and other stakeholders around the world.

Since 2020, we have been working on a multifaceted approach to end the challenge of COVID-19, currently focused on prevention through vaccination support, and identification and treatment of appropriate adult patients through drug support. Regardless of our success in fighting COVID, we still have a lot of work to do. Pfizer remains committed to the fight against COVID-19.

Making the Impossible Possible

COVID-19 Vaccine: Vaccination prevention of the target population is crucial in the fight against COVID-19. As a result, we set ourselves the challenge of making the unimaginable possible in 2020. In collaboration with BioNTech, we have commercialized a groundbreaking vaccine against COVID-19 using messenger RNA (mRNA) technology, a molecule that contains a message or recipe that prompts cells to make proteins that support natural mechanisms.

We worked hard to ensure that this vaccine could reach the market without compromising its properties, working closely with our members, investigators, regulators, other companies and governments. Our victory was made possible in part by Pfizer's long history of vaccine research, development and use, spanning more than 100 years. ”

Treatment for COVID-19: In early 2020, Pfizer recognized the urgency of the COVID-19 pandemic around the world and initiated a drug discovery program to create treatments for the SARS-CoV-2 virus to complement vaccination efforts. We assembled a multidisciplinary team of dedicated researchers to help develop drugs designed for COVID-19 patients at highest risk of progressing to severe COVID-19.

Pfizer researchers decided that an oral inhibitor of the protease would be included in the clinical trial. On December 22, 2021, the U. S. Food and Drug Administration (FDA) issued an Emergency Use Resolution (EUA) to treat patients diagnosed with COVID-19 disease to treat severe forms of the disease. On May 25, 2023, the FDA approved it for the treatment of mild and moderate COVID-19 in adults at high risk of progression to severe COVID-19, including hospitalization or death.

Since 2020, we have continued to increase production in high-risk countries to expand access to the vaccine and treatment in some countries, based on local consent or approval. Billions of Pfizer-BioNTech Covid-19 vaccines and tens of millions of courses of oral Covid-19 treatments have been distributed around the world.

We remain committed to making the Pfizer-BioNTech Covid-19 vaccine and oral antiviral treatments for COVID-19 widely, equitably, and affordably available to patients around the world, and we are working on individualized approaches with national governments and other appropriate partners.

Getting Ahead of COVID-19

Three years after the announcement of COVID-19 due to pandemia, in May 2023, the World Health Organization (WHO) and the U. S. Department of Health and Human Services (HMS) announced a Public Health Emergency (CHSZ) regarding COVID-19. 3. 4. While clinical and real-world data continue to show that existing COVID-19 vaccine options help protect against the virus, we continue to monitor scientific developments by studying new vaccine approaches that may be needed as the virus evolves. We also continue our COVID-19 clinical development program. This consists of completed and ongoing clinical trials to evaluate potential oral therapies for use in other groups of patients.

Our goal is to stay ahead of the virus and continue cutting-edge scientific developments that we believe can help patients in need. We are actively pursuing a multifaceted strategy to evaluate new therapeutic candidates and potential combination therapies.

At the same time, we believe that one of the best preventive measures to prevent the spread of COVID-19 is for all people who have the right to be vaccinated to adhere to the vaccination schedule and for people who have been infected with COVID-19 to be trained and encouraged to consult with their healthcare professionals about available treatments.

We remain committed to providing broad, equitable and affordable COVID-19 vaccines and POVID-19 COVID-19 Pfizer to patients around the world who are entitled to them. To that end, we will continue to work with national governments and other appropriate partners on individualized approaches. While the development of breakthrough treatments and vaccines against COVID-19 is crucial, we believe that we are not fulfilling our broader promise to patients if we do not work to make our vaccines and treatments available to everyone who needs them. ”

Pfizer COVID-19 Treatment Transition

Albert Barra announced that he has reached an agreement in principle with the US government to make Pfizer's oral antiviral drug for the treatment of COVID-19 more accessible to patients. This will allow the US to have a reliable stockpile for future use and will bring greater transparency to the commercial market for COVID products. This is the next logical step in Pfizer's relentless efforts aimed at ensuring that all patients who are entitled to it continue to have access to this potentially important drug.

This video contains statements of a predictive nature that involve inherent risks and uncertainties and actual results may differ materially from those expressed or implied in such statements. More detailed information is available in Pfizer's press releases. You should also read our reports filed with the U. S. Securities and Exchange Commission (SEC), including under the headings "Risk Factors" and "Forecasting Information and Factors That May Affect Our Future Operating Results," which also contain such significant risks and uncertainties. These reports are available on the PFizer. com website and on the U. S. Securities and Exchange Commission website.

A Multi-Pronged Approach to COVID-19

Learn how to vaccinate eligible individuals to fight Covid-19 and treat them with oral formulations.

Making & Distributing Our Vaccine

Pfizer is closely monitoring its drug supply as it progresses.

Severe COVID & High Risk Populations

What are severe forms of Covid-19? Learn about severe forms of COVID-19, their symptoms, sources of risk factors, and answers to frequently asked questions.

Recursos para Hispanohablantes (Resources for Spanish-Speakers)

Dr. Santiago Lopez provides information on medical topics, including vaccines, fake news, and clinical trials.

Previous button Next button

Frequently asked questions about Pfizer and Covid-19

• What is the difference between the updated Covid-19 vaccine and the Omicron bivalent vaccine adapted for this season?

Microbes that cause COVID-19, like influenza, are frequently mutated. Since September 2023, within 85 % of COVID-19 cases in the United States, 5 Omicron XBB shares have been caused by people who were vaccinated in the previous season, and their bodies have the ability to distinguish them. There is almost no chance to gain defense. The vaccine this season is compatible with the Omicron XBB. 1. 5 subspecies, and the previous dual vaccine is compatible with Omicron Ba. 4 and Ba. 5 subspecies.

This vaccine enters the steps that will not be engaged for at least two months from the last vaccination of the COVID-19 vaccine. If you need an additional vaccination 60, 000, consult your doctor or pharmacist. If you experienced Cobid-19 a while ago, everything for you need to continue vaccination accurately, but you are the right amount of the vaccine for three months from the start of the signs. You can delay access, or, if you have the first time we had flattering analysis.

You can do it so that you can do it so that you are actually a promise, everyone can quickly ignore these seemingly accurate {} people. can. 7

There is still a possibility of infection with COVID-19, and some have the highest risk of infection. As a result, basically, people who have been diagnosed with COVID-19 can be tested and treated. Therefore, for example, vaccines and treatment options are being tackled to reduce the control of COVID-19 in the world.

COVID-19 oral treatment can suit you even if you are vaccinated at the highest time when the risk of roles is the highest. Please consult your doctor for individual medical advice.

Clinical data and actual data have shown that COVID-19 vaccines help protect COVID-19 through difficulty and hospitalized risks. However, if you are still sloppy, you will notice the sign of COVID-19 and have a highly uniform moment of diseases in the difficult form, how quickly you can treat your doctor before stepping into steps. Do you want to consult?

Side effects are likely to differ depending on individual differences and vaccines used. Be sure to consult a medical specialist and make a decision according to your medical situation. Safety is an important interest for us, and Pfizer seriously accepts reports of side effects that may be related to our COVID-19 vaccine. However, hundreds of millions of people have been vaccinated by this vaccine without harm. It is important to note that any medicine or vaccine has side effects. 8 These side effects are strictly monitored during clinical trials to ensure that benefits exceed the risk. Detailed information from 9 is published on the CDC page "COVID-19 COVID-19 vaccination side effects". For more information about Faser's COVID-19 research, see the Coronavirus information page.

Important implementation consent

The Pfizer Bion Tech COVID-19 vaccine (formulation 2023-2024) is not approved or approved by FDA, but based on the EUA2019 (COVID-19) to prevent corona virus disease, the age of 6 years or older to 11 years old. Critical use for people up to age is approved by FDA. Clitical release of approved products justifies the critical release of medical products according to the FD & AMP; C method section 564 (B) (1), unless such approval is completed or the approval is withdrawn first. It is approved only during the review of the event. Please see the EUA fact seat on www. Cvvdaccine-us. com.

Application for approval for important use by the US Food and Pharmaceutical Bureau (FDA)

The US Food and Pharmaceutical Bureau (FDA) has an adult and pediatric patient (COVID-19), a mild to moderate severity, severe and moderate severity, with a high risk of progressing to severe COVID-19, including hospitalization or death. Approval of important use of Pax Robide as a treatment for 12 years or older and weighing 40 kg or more).

Paxlobide is approved only during the examination period during the examination period of the event that justifies the severe use of Paxlobide, based on the Food, Pharmaceutical, and Cosmetics Law 564 (B) (1), but is first terminated or canceled. Excludes.

• link

1. Seed of human koro navirus. https: // www. cdc. Gov/Coronavirus/Types. html.
2. Coronavirus infection (COVID-19) disease name and causative virus. WHO. Https: // www. Int/emergencies/DISEASES/NOVEL-CORONAVIRUS-2019/Technical US-that-casaisit. October 25, 2021 I visited.
3. World Health Organization (WHO). https: // www. int/new/item/05-05-2023-StateMent-in-ftety-COEMAG-COEMAGE-COEMAG-COR-COR Onavirus-Disease- (COVID-19 ) -A application for the 15th meeting of the MMSP (2005) emergency committee on pandemic. Published on May 5, 2023. Viewed May 8, 2023.
4. Health and social support service. https: // www. HS. GOV/Coronavirus/Covid-19-Public-heelth-omgence/index. html. Updated on May 5, 2023. Viewed May 8, 2023.
5. Diseases preventive prevention center. COVID DATA Tracker. Https: // cdc. Cdc. Gov/Covid-data-tracker/#variant-proPotions. The last update is September 2, 2023. Access on September 11, 2023.
6. US disease prevention management center. https: // www. CDC. GOV/Coronavirus/2019-NCOV/VACCINES/stay-on-to-date. html. HTML. Available on September 22, 2023.
7. Centers for Disease Control and Preventionon. https: // www. cdc. gov/cornavirus/2019-ncov/vaccines/expect. html. Final update: September 12, 2023. Viewing date: September 22, 2023.
8. Possibility of side effects of vaccine. https: // www. cdc. gov/vaccines/vac- gen/side-effects. htm. Access in July 2023.
9. Development and approval process. UNITED States Office Office Office Office Office Office Office Office Office Oversight. https: // www. fda. gov/drugs/drugs/development-approvel-process-drugs. Released on August 8, 2022. Viewed July 10, 2023.

Martha Stuart was a lifestyle expert, a big media world, and even the elderly care center. She recently told pfizer. com why she participated in the GOT YOURS program.

The concept of severe Civid-19 is scary, especially in the words itself, which is often understood and understood as self-awareness of severe Cobid-19. Mild or moderate.

When Dr. Cynthia J. Musante’s husband was infected with the Covid-19 virus, he was covered in fear and anxiety. But that anxiety disappeared in just 24 hours.

It has been several years since COVID-19 was declared a global pandemic.

Words like “quarantine” and “social distancing” have become a natural part of our vocabulary since 2020. But many of us no longer cost six feet apart in public or undergo quarantine for testing after COVID-19 infection.

Wait, a miracle? On the pfizer. com site? Some may think that comics are just a type of entertainment made up of fantastic characters and mythical plots. But over the years, comics have proven to reflect and even influence our society.

In 2020, as Pfizer and BioNTech continued to develop a Covid-19 vaccine, Julie Jenson was pondering how to distribute the vaccine to every country in the world, regardless of financial capacity.

On Tuesday, December 31, 2019, Chinese authorities alerted the World Health Organization (WHO) about a mysterious virus that had caused pneumonia in a small number of clustered cases in the city of Ujang. Shortly after, the new virus was identified as SARS-COV-2.

When the potential threat of COVID-19 became clear in early 2020, the Pfizer team began working together. Together, they worked to better understand the new virus. Hospitals were busy, and no one knew how to better treat the sick.

When the cold season begins, viruses tend to spread more easily. This is due to the fact that people spend more time in rooms where microorganisms can be transmitted from person to person through the air or close contact.